Overcoming imatinib resistance conferred by the BIM deletion polymorphism in chronic myeloid leukemia with splice-switching antisense oligonucleotides. The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.